349 related articles for article (PubMed ID: 8833398)
1. High-dose cytarabine and recombinant human granulocyte colony-stimulating factor for the treatment of resistant acute myelogenous leukemia.
Schiller G; Emmanoulides C; Iastrebner MC; Lee M; Naeim F
Leuk Lymphoma; 1996 Feb; 20(5-6):427-34. PubMed ID: 8833398
[TBL] [Abstract][Full Text] [Related]
2. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy.
Giralt S; Estey E; Albitar M; van Besien K; Rondón G; Anderlini P; O'Brien S; Khouri I; Gajewski J; Mehra R; Claxton D; Andersson B; Beran M; Przepiorka D; Koller C; Kornblau S; Kørbling M; Keating M; Kantarjian H; Champlin R
Blood; 1997 Jun; 89(12):4531-6. PubMed ID: 9192777
[TBL] [Abstract][Full Text] [Related]
3. Prolonged administration of all-trans retinoic acid in combination with intensive chemotherapy and G-CSF for adult acute myelogenous leukemia: single-centre pilot study in different risk groups.
Bassan R; Chiodini B; Lerede T; Giussani U; Oldani E; Buelli M; Rossi A; Viero P; Rambaldi A; Barbui T
Hematol J; 2002; 3(4):193-200. PubMed ID: 12189565
[TBL] [Abstract][Full Text] [Related]
4. Granulocyte colony-stimulating factor after intensive consolidation chemotherapy in acute myeloid leukemia: results of a randomized trial of the Groupe Ouest-Est Leucémies Aigues Myeloblastiques.
Harousseau JL; Witz B; Lioure B; Hunault-Berger M; Desablens B; Delain M; Guilhot F; Le Prise PY; Abgrall JF; Deconinck E; Guyotat D; Vilque JP; Casassus P; Tournilhac O; Audhuy B; Solary E
J Clin Oncol; 2000 Feb; 18(4):780-7. PubMed ID: 10673519
[TBL] [Abstract][Full Text] [Related]
5. Impact of granulocyte colony-stimulating factor use during induction for acute myelogenous leukemia in children: a report from the Children's Cancer Group.
Alonzo TA; Kobrinsky NL; Aledo A; Lange BJ; Buxton AB; Woods WG
J Pediatr Hematol Oncol; 2002 Nov; 24(8):627-35. PubMed ID: 12439034
[TBL] [Abstract][Full Text] [Related]
6. High-dose cytarabine, idarubicin, and granulocyte colony-stimulating factor remission induction therapy for previously untreated de novo and secondary adult acute myeloid leukemia.
Baer MR; Christiansen NP; Frankel SR; Brunetto VL; Mrózek K; Bloomfield CD; Herzig GP
Semin Oncol; 1993 Dec; 20(6 Suppl 8):6-12. PubMed ID: 7507264
[TBL] [Abstract][Full Text] [Related]
7. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A
Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
[TBL] [Abstract][Full Text] [Related]
8. Rapid engraftment after autologous transplantation utilizing marrow and recombinant granulocyte colony-stimulating factor-mobilized peripheral blood stem cells in patients with acute myelogenous leukemia.
Demirer T; Buckner CD; Appelbaum FR; Petersen FB; Rowley S; Weaver CH; Lilleby K; Sanders J; Chauncey T; Storb R
Bone Marrow Transplant; 1995 Jun; 15(6):915-22. PubMed ID: 7581091
[TBL] [Abstract][Full Text] [Related]
9. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol.
Martino R; Guardia R; Altés A; Sureda A; Brunet S; Sierra J
Haematologica; 1999 Mar; 84(3):226-30. PubMed ID: 10189387
[TBL] [Abstract][Full Text] [Related]
10. Timed-sequential chemotherapy with concomitant granulocyte colony-stimulating factor for newly diagnosed de novo acute myelogenous leukemia.
He XY; Pohlman B; Lichtin A; Rybicki L; Kalaycio M
Leukemia; 2003 Jun; 17(6):1078-84. PubMed ID: 12764371
[TBL] [Abstract][Full Text] [Related]
11. FLAG-IDA in the treatment of refractory/relapsed acute leukaemias: single centre study.
Hashmi KU; Khan B; Ahmed P; Raza S; Hussain I; Mahmood A; Iqbal H; Malik HS; Anwar M
J Pak Med Assoc; 2005 Jun; 55(6):234-8. PubMed ID: 16045091
[TBL] [Abstract][Full Text] [Related]
12. High-dose cytarabine as salvage therapy for relapsed or refractory acute myeloid leukemia--is more better or more of the same?
Wolach O; Itchaki G; Bar-Natan M; Yeshurun M; Ram R; Herscovici C; Shpilberg O; Douer D; Tallman MS; Raanani P
Hematol Oncol; 2016 Mar; 34(1):28-35. PubMed ID: 25689584
[TBL] [Abstract][Full Text] [Related]
13. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490).
Rowe JM; Andersen JW; Mazza JJ; Bennett JM; Paietta E; Hayes FA; Oette D; Cassileth PA; Stadtmauer EA; Wiernik PH
Blood; 1995 Jul; 86(2):457-62. PubMed ID: 7605984
[TBL] [Abstract][Full Text] [Related]
14. Timed sequential chemotherapy with concomitant granulocyte colony-stimulating factor for high-risk acute myelogenous leukemia: a single arm clinical trial.
He XY; Elson P; Pohlman B; Lichtin A; Hussein M; Andresen S; Kalaycio M
BMC Cancer; 2002 May; 2():12. PubMed ID: 12019034
[TBL] [Abstract][Full Text] [Related]
15. Autologous transplantation with peripheral blood stem cells collected after granulocyte colony-stimulating factor in patients with acute myelogenous leukemia.
Demirer T; Petersen FB; Bensinger WI; Appelbaum FR; Fefer A; Rowley S; Sanders J; Chauncey T; Storb R; Lilleby K; Buckner CD
Bone Marrow Transplant; 1996 Jul; 18(1):29-34. PubMed ID: 8831992
[TBL] [Abstract][Full Text] [Related]
16. Combination regimen of cladribine (2-chlorodeoxyadenosine), cytarabine and G-CSF (CLAG) as induction therapy for patients with relapsed or refractory acute myeloid leukemia.
Robak T; Wrzesień-Kuś A; Lech-Marańda E; Kowal M; Dmoszyńska A
Leuk Lymphoma; 2000 Sep; 39(1-2):121-9. PubMed ID: 10975390
[TBL] [Abstract][Full Text] [Related]
17. Mito-flag as salvage therapy for relapsed and refractory acute myeloid leukemia.
Hänel M; Friedrichsen K; Hänel A; Herbst R; Morgner A; Neser S; Nicklisch M; Teich M; Ehninger G; Fiedler F
Onkologie; 2001 Aug; 24(4):356-60. PubMed ID: 11574763
[TBL] [Abstract][Full Text] [Related]
18. Granulocyte-macrophage colony-stimulating factor (GM-CSF) priming with successive concomitant low-dose Ara-C for elderly patients with secondary/refractory acute myeloid leukemia or advanced myelodysplastic syndrome.
Rossi HA; O'Donnell J; Sarcinelli F; Stewart FM; Quesenberry PJ; Becker PS
Leukemia; 2002 Mar; 16(3):310-5. PubMed ID: 11896533
[TBL] [Abstract][Full Text] [Related]
19. Granulocyte colony-stimulating factor shortens duration of critical neutropenia and prolongs disease-free survival after sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy for refractory and relapsed acute myeloid leukemia. German AML Cooperative Group.
Kern W; Aul C; Maschmeyer G; Kuse R; Kerkhoff A; Grote-Metke A; Eimermacher H; Kubica U; Wörmann B; Büchner T; Hiddemann W
Ann Hematol; 1998 Sep; 77(3):115-22. PubMed ID: 9797080
[TBL] [Abstract][Full Text] [Related]
20. Effect of low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndrome.
Wu L; Li X; Su J; Chang C; He Q; Zhang X; Xu L; Song L; Pu Q
Leuk Lymphoma; 2009 Sep; 50(9):1461-7. PubMed ID: 19672772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
